Recent vaccine development for human metapneumovirus

J. Ren, T. Phan, Xiaoyong Bao

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Human metapneumovirus (hMPV) and respiratory syncytial virus, its close family member, are two major causes of lower respiratory tract infection in the paediatric population. hMPV is also acommon cause of worldwide morbidity and mortality in immunocompromised patients and older adults. Repeated infections occur often, demonstrating a heavy medical burden. However, there is currently no hMPV-specific prevention treatment. This review focuses on the current literature on hMPV vaccine development. We believe that a better understanding of the role(s) of viral proteins in host responses might lead to efficient prophylactic vaccine development.

Original languageEnglish (US)
Pages (from-to)1515-1520
Number of pages6
JournalJournal of General Virology
Volume96
Issue number7
DOIs
StatePublished - Jul 1 2015

Fingerprint

Metapneumovirus
Vaccines
Human respiratory syncytial virus
Immunocompromised Host
Viral Proteins
Respiratory Tract Infections
Pediatrics
Morbidity
Mortality
Infection
Population

ASJC Scopus subject areas

  • Virology

Cite this

Recent vaccine development for human metapneumovirus. / Ren, J.; Phan, T.; Bao, Xiaoyong.

In: Journal of General Virology, Vol. 96, No. 7, 01.07.2015, p. 1515-1520.

Research output: Contribution to journalArticle

Ren, J. ; Phan, T. ; Bao, Xiaoyong. / Recent vaccine development for human metapneumovirus. In: Journal of General Virology. 2015 ; Vol. 96, No. 7. pp. 1515-1520.
@article{264fe36dcf224bdfa5a480056b3f4ffe,
title = "Recent vaccine development for human metapneumovirus",
abstract = "Human metapneumovirus (hMPV) and respiratory syncytial virus, its close family member, are two major causes of lower respiratory tract infection in the paediatric population. hMPV is also acommon cause of worldwide morbidity and mortality in immunocompromised patients and older adults. Repeated infections occur often, demonstrating a heavy medical burden. However, there is currently no hMPV-specific prevention treatment. This review focuses on the current literature on hMPV vaccine development. We believe that a better understanding of the role(s) of viral proteins in host responses might lead to efficient prophylactic vaccine development.",
author = "J. Ren and T. Phan and Xiaoyong Bao",
year = "2015",
month = "7",
day = "1",
doi = "10.1099/vir.0.000083",
language = "English (US)",
volume = "96",
pages = "1515--1520",
journal = "Journal of General Virology",
issn = "0022-1317",
publisher = "Society for General Microbiology",
number = "7",

}

TY - JOUR

T1 - Recent vaccine development for human metapneumovirus

AU - Ren, J.

AU - Phan, T.

AU - Bao, Xiaoyong

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Human metapneumovirus (hMPV) and respiratory syncytial virus, its close family member, are two major causes of lower respiratory tract infection in the paediatric population. hMPV is also acommon cause of worldwide morbidity and mortality in immunocompromised patients and older adults. Repeated infections occur often, demonstrating a heavy medical burden. However, there is currently no hMPV-specific prevention treatment. This review focuses on the current literature on hMPV vaccine development. We believe that a better understanding of the role(s) of viral proteins in host responses might lead to efficient prophylactic vaccine development.

AB - Human metapneumovirus (hMPV) and respiratory syncytial virus, its close family member, are two major causes of lower respiratory tract infection in the paediatric population. hMPV is also acommon cause of worldwide morbidity and mortality in immunocompromised patients and older adults. Repeated infections occur often, demonstrating a heavy medical burden. However, there is currently no hMPV-specific prevention treatment. This review focuses on the current literature on hMPV vaccine development. We believe that a better understanding of the role(s) of viral proteins in host responses might lead to efficient prophylactic vaccine development.

UR - http://www.scopus.com/inward/record.url?scp=84938406908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938406908&partnerID=8YFLogxK

U2 - 10.1099/vir.0.000083

DO - 10.1099/vir.0.000083

M3 - Article

VL - 96

SP - 1515

EP - 1520

JO - Journal of General Virology

JF - Journal of General Virology

SN - 0022-1317

IS - 7

ER -